Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

Author
Ridolfi, Antonia
Ozguroglu, Mustafa
Arce, Christina H.
Lin, Chinjune
Bachelot, Thomas Denis
Cardoso, Fatima
Villanueva, Cristian
Royce, Melanie
Cruz, Felipe
Debled, Marc
Hegg, Roberto
Toyama, Tatsuya
Falkson, Carla Isadora
Jeong, Joon
Srimuninnimit, Vichien
Gradishar, William John
Azevedo, Sergio J.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/25912
https://doi.org/10.1200/jco.2017.35.15_suppl.1010
Collections